<DOC>
	<DOCNO>NCT03062618</DOCNO>
	<brief_summary>This study consist three part : single oral dose escalation healthy volunteer ( Part A ) , multiple oral dose escalation healthy volunteer ( Part B ) participants chronic plaque psoriasis ( Part C )</brief_summary>
	<brief_title>A Study PRCL-02 Healthy Volunteers Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Parts A B Be 18 55 year old Be healthy absence clinically significant illness Male participant must agree use medically accept method contraception sexual partner study , 90 day Female participant must postmenopausal surgically sterile Have venous access sufficient blood sample Be nonsmoker Part C Be 18 65 year old Have chronic plaque psoriasis base confirm diagnosis plaque least 6 month Have least 4 evaluable plaque locate least 2 body region Parts A B Significant abnormalities vital sign , laboratory test , electrocardiogram , history heart disease , allergy , infection Hepatic renal impairment Hepatitis B , Hepatitis C , Human Immunodeficiency Virus ( HIV ) Female participant pregnant breast feeding Recent ongoing infection History alcohol drug abuse Current recent enrollment clinical trial judge compatible study Part C Have highly active psoriatic arthritis Have pustular , erythrodermic and/or guttate form psoriasis Have clinicallysignificant flare psoriasis last 12 week Currently recently take certain prescribed therapy psoriasis Use select topical treatment within 4 week prior start study ( use emollient without urea allow , except one lesion biopsy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>